Report Overview

The HIV/AIDS drugs market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Kenya market for HIV/AIDS treatment has been expanding owing to the high burden of disease in the country. Kenya is home to one of the world's worst HIV and AIDS epidemics. Approximately 1.5 million people are living with HIV in 2019, and an estimated 1 million children have been orphaned by the virus.Although, the prevalence has declined, now stands at 4.7% according to CDC (Centre of Disease Control), many people in Kenya are still not being reached with HIV prevention and treatment services. According KENPHIA, the prevalence of HIV in women is at 6.6%, twice that in men at 3.1%. The gender disparity in the burden of HIV is even greater than 3 times in between the ages of 20-34 years. High prevalence in the country may be attributed to low levels of awareness about HIV risk among women, increase in people who inject drugs and unprotected sex with injected persons.



Market Drivers

Kenya HIV Diagnosis & Treatment Market is growing moderately due to decline in the prevalence of HIV/AIDS. The prevalence has declined from 6.7% in 2004 to 4.7% in 2019.

HIV/AIDS drug market is driven by the high burden of HIV/AIDS. Kenya has the third-largest HIV epidemic in the world with approximately 1.5 million people living with HIV/AIDS. In addition, increasing product pipeline for treating HIV/AIDS expected to create high demand. HIV/AIDS treatment market is driven by increasing governments and regulatory bodies support by means of research and development investment, fast track approval for newer treatments for this disease.

Kenyas health authorities have launcheda new way to reduce the spread of HIV among its people. Thisis pre-exposure prophylaxis(PrEP), joins other prevention and treatment methods already in use in Kenya.

It involves giving antiretroviral (ARV) drugs to people who are not infected with HIV but are at high risk of infection. Taking the drug reduces the chances of HIV infection.

Low rate of voluntary screening for the disease is a major restraint for the market. Awareness about diagnostic tests for HIV infection is extremely low in countries in Africa. Hence, companies are facing challenges in penetrating the market in the region. Moreover, several low- and middle-income countries depend on government grants for provision of rapid diagnostic tests in the event of an epidemic. Therefore, their direct reach to customers is weak. These factors hamper the market in the region.